Shares of Novanta surged 12.9% to $172.89 after the precision-technology supplier posted second-quarter results that beat Wall Street across the board — and then raised its outlook for the rest of the year. The question now is whether the stock, already near its 52-week high, has priced in the good news or is still catching up to a fundamentally stronger company.

  • The Core Business Is Growing at Its Fastest Pace in Three Years. Novanta's 9.3% organic revenue growth — stripping out currency effects — was its highest since the first quarter of 2023.

Revenue of $265.8 million beat consensus estimates of $262.3 million, and adjusted EPS of $0.89 topped the $0.83 forecast by 7.2%. That matters because organic growth — sales gains from existing operations, not acquisitions — is the purest measure of demand. Adjusted gross margins widened to 47.1% from 46.1% a year earlier , meaning Novanta is growing and becoming more profitable per dollar of revenue.

  • The Guidance Raise Is Bigger Than It Looks. Novanta now expects full-year revenue of $1.13–$1.14 billion (over 15% growth), adjusted EBITDA of $273–$278 million (over 24% growth), and adjusted EPS of $3.68–$3.74 (over 12% growth). At the start of the year, the company guided revenue to just $1.03–$1.05 billion — an $85 million upward revision in two quarters. Third-quarter revenue guidance of ~$302 million came in 14.9% above analyst estimates , signaling confidence isn't fading.

  • A $1.2 Billion Acquisition Changes the Company's Profile. Novanta closed its purchase of Riverpoint Medical on July 23 for roughly $1.2 billion in cash, plus a potential $250 million milestone payment.

The deal is expected to double recurring medical-consumables revenue to roughly $300 million and push medical end-market exposure to 60% of total sales. That shifts Novanta toward steadier, repeat-purchase revenue — but it required drawing $616 million in debt , lifting leverage meaningfully.

  • Insiders Have Been Steady Sellers. Over the past six months, insiders logged 34 sales and zero purchases, with CEO Matthijs Glastra alone selling 47,500 shares for roughly $7 million.

Sales were executed under a pre-arranged trading plan , not panic selling — but the imbalance still warrants attention given today's elevated price.